Results · Apr-Jun 2026
Supriya Lifescience Q1 FY27 results
Sales grew 31% to ₹190 crore from ₹145 crore in Apr-Jun 2025.
Operating profit fell 8% to ₹47.5 crore, an operating margin of 25.0% (down 10.6 points from a year ago).
Net profit fell 31% to ₹24 crore from ₹34.8 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −31%, net profit −68%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 189.7 | 145.1 | +31% |
| Operating profit (EBITDA) | 47.5 | 51.7 | −8% |
| Operating margin | 25.0% | 35.6% | −10.6 pts |
| Net profit | 24.0 | 34.8 | −31% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.